Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03569371 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
A Phase 2 study of Hidradenitis Suppurativa, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 4
- Study locations
NCT03569371: Completed Phase 2 study of Hidradenitis Suppurativa, sponsored by Incyte Corporation.
NCT03569371 is a Phase 2 study of Hidradenitis Suppurativa that has completed, run by Incyte Corporation. The registered enrollment target is 10 participants, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03569371, a Phase 2 study of Hidradenitis Suppurativa, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to assess the safety of INCB054707 in men and women with moderate to severe hidradenitis suppurativa (HS).
Primary Outcome
A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after first dose of study drug.
Conditions Studied
Interventions
- DRUG INCB054707
Study Locations (4)
California
- Investigative Site - Los Angeles
Florida
- Investigative Site - Tampa
New York
- Investigative Site - New York
Pennsylvania
- Investigative Site - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-07-17 |
| Est. Completion | 2019-04-22 |
| Phase | Phase 2 |
What the finished NCT03569371 record still lists
NCT03569371 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which INCB054707 is the first listed.
NCT03569371 reports a single indexed study location in California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT03569371 about?
NCT03569371 is a clinical study titled "A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa". The purpose of this study is to assess the safety of INCB054707 in men and women with moderate to severe hidradenitis suppurativa (HS).
What is the current status of trial NCT03569371?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2018-07-17. Estimated completion is 2019-04-22.
What conditions does trial NCT03569371 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT03569371?
The interventions under investigation include: INCB054707 (DRUG).
Who is sponsoring clinical trial NCT03569371?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03569371 being conducted?
This trial has 4 study locations across California, Florida, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03569371's enrollment target sits among peer trials
10 50th of 52 higher than 2 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI